Your session is about to expire
← Back to Search
Arm 1A: Volrustomig dose regimen 1 + Carboplatin and Pemetrexed for Non-Small Cell Lung Cancer (eVOLVE-01 Trial)
Phase 2
Waitlist Available
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2.4 years
Awards & highlights
Summary
Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.
Eligible Conditions
- Non-Small Cell Lung Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 2.4 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2.4 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Objective Response rate (ORR)
Secondary study objectives
Area Under the Curve (AUC)
Disease Control Rate (DCR)
Duration of Response (DOR)
+6 moreTrial Design
2Treatment groups
Experimental Treatment
Group I: Arm 1A: Volrustomig dose regimen 1 + Carboplatin and PemetrexedExperimental Treatment3 Interventions
Volrustomig priming dose followed by volrustomig dosing regimen 1 in combination with carboplatin and pemetrexed.
Group II: Arm 1 B Volrustomig dose regimen 2 + Carboplatin and PemetrexedExperimental Treatment3 Interventions
Volrustomig priming dose followed by volrustomig dosing regimen 2 in combination with carboplatin and pemetrexed.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Carboplatin
2014
Completed Phase 3
~6120
Pemetrexed
2014
Completed Phase 3
~5550
Find a Location
Who is running the clinical trial?
AstraZenecaLead Sponsor
4,352 Previous Clinical Trials
288,646,689 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger